Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.

Nitta SI, Hashimoto M, Kazuki Y, Takehara S, Suzuki H, Oshimura M, Akita H, Chiba K, Kobayashi K.

AAPS J. 2018 Apr 9;20(3):61. doi: 10.1208/s12248-018-0186-9.

PMID:
29858698
2.

Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity.

Aubry AF, Dean B, Diczfalusy U, Goodenough A, Iffland A, McLeod J, Weng N, Yang Z.

AAPS J. 2016 Sep;18(5):1056-1066. doi: 10.1208/s12248-016-9949-3. Epub 2016 Jun 27. Review.

PMID:
27350147
3.

Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.

Mao J, Martin I, McLeod J, Nolan G, van Horn R, Vourvahis M, Lin YS.

Drug Metab Rev. 2017 Feb;49(1):18-34. doi: 10.1080/03602532.2016.1239630. Epub 2016 Oct 20. Review.

PMID:
27718639
4.

Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS.

Huang MQ, Lin W, Wang W, Zhang W, Lin ZJ, Weng N.

Biomed Chromatogr. 2014 Jun;28(6):794-801. doi: 10.1002/bmc.3131.

PMID:
24861746
5.

Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals.

Hasan M, Siegmund W, Oswald S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:193-199. doi: 10.1016/j.jchromb.2016.08.006. Epub 2016 Aug 5.

PMID:
27565568
6.

4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.

Li K, Zhao S, Zhang L, Wu X, Shu P, Wang Y, Feng H, Gu Z, Han Hsu H.

Drug Metab Dispos. 2014 May;42(5):839-43. doi: 10.1124/dmd.114.057224. Epub 2014 Mar 4.

PMID:
24595680
7.

Cholesterol 25-hydroxylation activity of CYP3A.

Honda A, Miyazaki T, Ikegami T, Iwamoto J, Maeda T, Hirayama T, Saito Y, Teramoto T, Matsuzaki Y.

J Lipid Res. 2011 Aug;52(8):1509-16. doi: 10.1194/jlr.M014084. Epub 2011 May 16.

8.

CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.

Josephson F, Bertilsson L, Böttiger Y, Flamholc L, Gisslén M, Ormaasen V, Sönnerborg A, Diczfalusy U.

Eur J Clin Pharmacol. 2008 Aug;64(8):775-81. doi: 10.1007/s00228-008-0492-8. Epub 2008 May 6.

PMID:
18458892
9.

4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.

Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, Kim JW, Aklillu E, Gustafsson LL, Bertilsson L.

Pharmacogenet Genomics. 2008 Mar;18(3):201-8. doi: 10.1097/FPC.0b013e3282f50ee9.

PMID:
18300941
10.

Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.

Gebeyehu E, Engidawork E, Bijnsdorp A, Aminy A, Diczfalusy U, Aklillu E.

Pharmacogenomics J. 2011 Apr;11(2):130-7. doi: 10.1038/tpj.2010.16. Epub 2010 Mar 16.

PMID:
20231858
11.

4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.

Diczfalusy U, Nylén H, Elander P, Bertilsson L.

Br J Clin Pharmacol. 2011 Feb;71(2):183-9. doi: 10.1111/j.1365-2125.2010.03773.x. Review.

12.

4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.

Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L.

Br J Clin Pharmacol. 2009 Jan;67(1):38-43. doi: 10.1111/j.1365-2125.2008.03309.x. Epub 2008 Nov 6.

13.

Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.

Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, Diczfalusy U.

J Biol Chem. 2001 Oct 19;276(42):38685-9. Epub 2001 Aug 20.

14.

Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.

Kim AH, Kim B, Rhee SJ, Lee Y, Park JS, Lee SM, Kim SM, Lee S, Yu KS, Jang IJ, Cho JY.

Drug Metab Pharmacokinet. 2018 Jun;33(3):173-178. doi: 10.1016/j.dmpk.2018.04.004. Epub 2018 Apr 25.

PMID:
29759884
15.

Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy.

Wide K, Larsson H, Bertilsson L, Diczfalusy U.

Br J Clin Pharmacol. 2008 May;65(5):708-15. doi: 10.1111/j.1365-2125.2007.03078.x. Epub 2008 Feb 12.

16.

LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume.

Xu Y, Yuan Y, Smith L, Edom R, Weng N, Mamidi R, Silva J, Evans DC, Lim HK.

J Pharm Biomed Anal. 2013 Nov;85:145-54. doi: 10.1016/j.jpba.2013.07.016. Epub 2013 Jul 25.

PMID:
23948760
17.

CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine.

Naito T, Kubono N, Ishida T, Deguchi S, Sugihara M, Itoh H, Kanayama N, Kawakami J.

Drug Metab Pharmacokinet. 2015 Dec;30(6):419-24. doi: 10.1016/j.dmpk.2015.08.008. Epub 2015 Sep 3.

PMID:
26654672
18.

Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction.

Xue YJ, Hoffmann M, Tong Z, Wu XI, Vallejo M, Melo B, Ye Y, Thomas M, Liu Y, Weiss D, Surapaneni S.

Bioanalysis. 2016 Feb;8(3):215-28. doi: 10.4155/bio.15.241. Epub 2016 Jan 25.

PMID:
26805594
19.

Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.

Nylén H, Sergel S, Forsberg L, Lindemalm S, Bertilsson L, Wide K, Diczfalusy U.

Eur J Clin Pharmacol. 2011 Jul;67(7):715-22. doi: 10.1007/s00228-010-0984-1. Epub 2011 Jan 19.

PMID:
21246351
20.

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

de Graan AJ, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.

Br J Clin Pharmacol. 2015 Sep;80(3):560-8. doi: 10.1111/bcp.12707. Epub 2015 Aug 12.

Supplemental Content

Support Center